AET * Amgen Inc * Arecor Ltd * Biogen Idec * Boehringer Ingelheim Pharmaceutical * Bristol Myers Squibb * Celestial Biologicals * Celltrion Inc * Center for Medicine in the Public Interest * CEVEC Pharmaceuticals GmbH * Decision Resources * Dr Swamys Lab * Eden Biodesign Inc * EMD Millipore * Engel & Novitt * Express Scripts Inc * Fish & Richardson * Fuld & Company * Greenblum & Bernstein PLC * Hospira Australia * Johnson & Johnson * KBI Biopharma * Ken Pang * Makovsky & Co Inc * Merck & Co Inc * Momenta Pharmaceuticals Inc * Montclair Bioequivalence Services LLC * MPM Capital * NIST National Institiute of Standards and Technology * Novartis Pharmaceuticals * Panacea Pharmaceuticals * Percivia LLC * Pfizer * PPD Inc * Quintiles * Ropes & Gray LLP * Sandoz Inc * Sanofi Aventis * Schiff Hardin LLP * Smithers Group * SpringLeaf Therapeutics Inc * STC Biologics Inc * Synthon Pharmaceuticals Inc * Technology Catalysts Corporation * Teva Neuroscience * The Texas A&M University System * Valin Technologies * Vital HealthPoint *
Wolters Kluwer
IIR's 3rd Annual Business of Biosimilars & Biobetters, taking place September 19-21 in Boston, is designed to help you develop effective strategies to navigate scientific, regulatory, economic and legal challenges to remain competitive in commercializing your biosimilar portfolio in the United States and abroad.
For more information on the speakers and the presentation at the event, download the brochure here.
As a reader of the Future of Biopharma blog, if you register before September 9 using code XP1686BLOG, you'll receive 1 complimentary workshop of your choice! If you have any questions about the event, please feel free to contact Jennifer Pereira at jpereira@iirusa.com.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment